ATI-50002 for Alopecia Areata Eyebrow Hair Loss Trial Findings

Update on ATI-50002:

In June 2018 we reported on a new clinical trial being carried out by Aclaris Therapeutics into ATI-50002, a potential eyebrow hair loss solution for people with the autoimmune disorder Alopecia Areata.

ATI-50002 is a topical janus kinase inhibitor (JAK inhibitor) and one of a number of medications the company has been developing for the treatment of the various forms of autoimmune alopecia.

On 11th December 2019 the results from this Phase 1 study were published on the clinicaltrials.gov database.

However, of the data findings that were released, it appears only one person - a white male aged between 18 and 65 years - took part.

Whilst it does acknowledge that the man completed the six month study, his results are listed as 'not specified'.

No adverse events - including serious side effects - were reported, though, as the eyebrow hair regrowth results are not provided and the trial is so small in scale, unfortunately there is little to be made of this information for now.

Despite making a 'strong commitment' in 2016 to the development of JAK inhibitors for the treatment of all forms of Alopecia Areata, Aclaris Therapeutics terminated its development of certain novel hair loss drugs earlier in 2019. This came after a number of disappointing trial results.

There has yet to be any official word on the trial outcome from Aclaris, with mentions of the study in the trials and pipeline sections of the pharmaceutical company's website being notably absent.

Eyebrow hairloss is generally associated with Alopecia Totalis; this is the second most severe form of Alopecia Areata. It causes baldness of the entire scalp and can also cause additional shedding of facial hair, including brows, eyelashes, beard and nasal hair.

There are currently no MHRA-licensed nor FDA-approved Alopecia Areata treatments for either adults or children with this condition. This is why the medical and pharmaceutical communities are working hard to find appropriate solutions.

There are a number of 'off-license' therapies and medications which have been shown to promote hair regrowth, including immunotherapy, steroids and, where the patient is an adult with patchy hair loss of the scalp only, high strength minoxidil.

For adults with baldness that involves areas other than the scalp, and for under 16s, your GP or dermatologist should be your first port of call for assistance. For those whose hair loss is limited to sudden onset bald patches on the scalp, specialists at a dedicated hair loss clinic can provide a professional diagnosis and treatment recommendations.